Skip to main content

Table 3 EGFR and HER2 silver in situ hybridization in intestinal-type adenocarcinomas according to anatomical location

From: EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus

Gene copy number status Distal oesophagus GOJ/cardia Corpus Antrum/pylorus Total P value
N = 20 (%) N = 63 (%) N = 65 (%) N = 72 (%) N = 220 (%) (χ 2 test)c
EGFR amplificationa
 Yes 5 (16.1) 13 (41.9) 2 (6.5) 11 (35.5) 31 (100.0) 0.013d
 No 15 (7.9) 50 (26.5) 63 (33.3) 61 (32.3) 189 (100.0)  
 Total N of amplification (%) 5/20 (25.0) 13/63 (20.6) 2/65 (3.1) 11/72 (15.3) 31/220 (14.1)  
HER2 amplificationa
 Yes 5 (17.2) 9 (31.0) 9 (31.0) 6 (20.7) 29 (100.0) NS
 No 15 (7.9) 54 (28.3) 56 (29.3) 66 (34.6) 191 (100.0)  
 Total N of amplification (%) 5/20 (25.0) 9/63 (14.3) 9/65 (13.8) 6/72 (8.3) 29/220 (13.2)  
EGFR and HER2 co-amplificationa
 Yes 2 (25.0) 1 (12.5) 1 (12.5) 4 (50.0) 8 (100.0) NS
 No 18 (8.5) 62 (29.2) 64 (30.2) 68 (32.1) 212 (100.0)  
 Total N of co-amplification (%) 2/20 (10.0) 1/63 (1.6) 1/65 (1.5) 4/72 (5.6) 8/220 (3.6)  
P value (Fisher’s exact test)b NS NS NS 0.004d   
  1. IHC immunohistochemistry, GOJ gastro-oesophageal junction, GCN gene copy number, NS not significant
  2. aAmplification, GCN >10 for EGFR; GCN >6 for HER2
  3. bConcordant vs. discordant EGFR and HER2 amplification status
  4. cDistal oesophagus, GOJ and cardia vs. corpus
  5. dStatistically significant